Citadel Advisors LLC Takes $629,000 Position in Taro Pharmaceutical Industries Ltd. (TARO)

Citadel Advisors LLC bought a new position in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,617 shares of the company’s stock, valued at approximately $629,000.

Several other hedge funds and other institutional investors have also bought and sold shares of TARO. FMR LLC grew its stake in shares of Taro Pharmaceutical Industries by 42.2% in the second quarter. FMR LLC now owns 466,590 shares of the company’s stock worth $52,286,000 after purchasing an additional 138,353 shares during the last quarter. River Road Asset Management LLC grew its stake in shares of Taro Pharmaceutical Industries by 33.3% in the second quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock worth $7,337,000 after purchasing an additional 16,350 shares during the last quarter. Aperio Group LLC grew its stake in shares of Taro Pharmaceutical Industries by 46.9% in the second quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock worth $5,696,000 after purchasing an additional 16,233 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Taro Pharmaceutical Industries by 19.0% in the second quarter. Acadian Asset Management LLC now owns 42,799 shares of the company’s stock worth $4,796,000 after purchasing an additional 6,824 shares during the last quarter. Finally, Eagle Global Advisors LLC bought a new stake in shares of Taro Pharmaceutical Industries in the second quarter worth about $616,000. 14.20% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Citadel Advisors LLC Takes $629,000 Position in Taro Pharmaceutical Industries Ltd. (TARO)” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2017/10/08/citadel-advisors-llc-takes-629000-position-in-taro-pharmaceutical-industries-ltd-taro.html.

Several analysts recently issued reports on TARO shares. BidaskClub raised Taro Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. TheStreet cut Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a research note on Thursday, June 15th.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) opened at 114.20 on Friday. Taro Pharmaceutical Industries Ltd. has a one year low of $92.28 and a one year high of $124.52. The firm has a 50-day moving average of $106.86 and a 200 day moving average of $111.44. The stock has a market capitalization of $4.62 billion, a price-to-earnings ratio of 11.63 and a beta of 0.65.

Taro Pharmaceutical Industries Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply